Solana Company (26H1)
XMUN 
Summary
26H1 Chart
Solana Company (HSDT) Q2 2026 Earnings Call Transcript
Solana Company (HSDT) Q2 2026 Earnings Call Transcript
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates
Solana Company (HSDT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $79.73 per share a year ago.
Solana Q2 Earnings Call Highlights
Solana NASDAQ: HSDT reported second-quarter 2026 revenue of $2.5 million, driven primarily by staking rewards from its digital asset treasury, as the company continued building its institutional advisory, validator infrastructure and treasury businesses across Asia-Pacific.
Solana Company (26H1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Solana Company ever had a stock split?
Solana Company Profile
| Financial Services Industry | Financials Sector | Dane Carl Andreeff CEO | XMUN Exchange | US42328V8761 ISIN |
| US Country | 21 Employees | 4 Jan 2021 Last Dividend | 1 Jul 2025 Last Split | 27 Jun 2014 IPO Date |
Overview
Helius Medical Technologies, Inc. stands out as a pioneering company in the realm of neurotechnology with its focus straddling the development, licensing, and procurement of innovative non-implantable technologies aimed at ameliorating symptoms attributable to neurological disorders or injuries. Founded in 2014, this firm has set its base in Newtown, Pennsylvania, marking its commitment towards delivering groundbreaking solutions to enhance neurological health and function.
Products and Services
- Portable Neuromodulation Stimulator (PoNS™)
This avant-garde, non-surgical medical device represents Helius Medical Technologies' flagship offering. It’s specifically engineered for short-term treatment of gait deficits stemming from multiple sclerosis and balance deficits due to mild-to-moderate traumatic brain injury. A key aspect of its application involves concurrent utilization with supervised therapeutic exercises, highlighting its role as a supplementary treatment modality designed to foster improved neurological function.
